» Articles » PMID: 33135684

Pre-clustering Data Sets Using Cluster4x Improves the Signal-to-noise Ratio of High-throughput Crystallography Drug-screening Analysis

Overview
Specialty Biochemistry
Date 2020 Nov 2
PMID 33135684
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Drug and fragment screening at X-ray crystallography beamlines has been a huge success. However, it is inevitable that more high-profile biological drug targets will be identified for which high-quality, highly homogenous crystal systems cannot be found. With increasing heterogeneity in crystal systems, the application of current multi-data-set methods becomes ever less sensitive to bound ligands. In order to ease the bottleneck of finding a well behaved crystal system, pre-clustering of data sets can be carried out using cluster4x after data collection to separate data sets into smaller partitions in order to restore the sensitivity of multi-data-set methods. Here, the software cluster4x is introduced for this purpose and validated against published data sets using PanDDA, showing an improved total signal from existing ligands and identifying new hits in both highly heterogenous and less heterogenous multi-data sets. cluster4x provides the researcher with an interactive graphical user interface with which to explore multi-data set experiments.

Citing Articles

Mapping Protein Conformational Landscapes from Crystallographic Drug Fragment Screens.

Saeed A, Klureza M, Hekstra D J Chem Inf Model. 2024; 64(23):8937-8951.

PMID: 39530154 PMC: 11633654. DOI: 10.1021/acs.jcim.4c01380.


Mapping protein conformational landscapes from crystallographic drug fragment screens.

Saeed A, Klureza M, Hekstra D bioRxiv. 2024; .

PMID: 39131376 PMC: 11312500. DOI: 10.1101/2024.07.29.605395.


An expanded trove of fragment-bound structures for the allosteric enzyme PTP1B from computational reanalysis of large-scale crystallographic data.

Mehlman T, Ginn H, Keedy D Structure. 2024; 32(8):1231-1238.e4.

PMID: 38861991 PMC: 11316629. DOI: 10.1016/j.str.2024.05.010.


A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity.

Liu C, Zhou D, Dijokaite-Guraliuc A, Supasa P, Duyvesteyn H, Ginn H Cell Rep Med. 2024; 5(5):101553.

PMID: 38723626 PMC: 11148769. DOI: 10.1016/j.xcrm.2024.101553.


An expanded view of ligandability in the allosteric enzyme PTP1B from computational reanalysis of large-scale crystallographic data.

Mehlman T, Ginn H, Keedy D bioRxiv. 2024; .

PMID: 38260327 PMC: 10802458. DOI: 10.1101/2024.01.05.574428.


References
1.
Collins P, Douangamath A, Talon R, Dias A, Brandao-Neto J, Krojer T . Achieving a Good Crystal System for Crystallographic X-Ray Fragment Screening. Methods Enzymol. 2018; 610:251-264. DOI: 10.1016/bs.mie.2018.09.027. View

2.
Diederichs K . Dissecting random and systematic differences between noisy composite data sets. Acta Crystallogr D Struct Biol. 2017; 73(Pt 4):286-293. PMC: 5379934. DOI: 10.1107/S2059798317000699. View

3.
Glockner S, Heine A, Klebe G . A Proof-of-Concept Fragment Screening of a Hit-Validated 96-Compounds Library against Human Carbonic Anhydrase II. Biomolecules. 2020; 10(4). PMC: 7226012. DOI: 10.3390/biom10040518. View

4.
Keedy D, Hill Z, Biel J, Kang E, Rettenmaier T, Brandao-Neto J . An expanded allosteric network in PTP1B by multitemperature crystallography, fragment screening, and covalent tethering. Elife. 2018; 7. PMC: 6039181. DOI: 10.7554/eLife.36307. View

5.
Forster A, Schulze-Briese C . A shared vision for macromolecular crystallography over the next five years. Struct Dyn. 2019; 6(6):064302. PMC: 6892709. DOI: 10.1063/1.5131017. View